此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO) (CINCAN-1)

2020年9月1日 更新者:Zealand University Hospital

Chemotherapy induced peripheral neuropathy (CIPN) is among the most feared side effects to cancer treatment. The development of CIPN can lead to discontinuation or omission of antineoplastic drugs, possibly affecting efficacy of cancer treatment. There is a lack of knowledge about the natural course of CIPN and to this date, there are no available methods for the early detection of CIPN. With no effective prevention or treatment options, the condition has severe impact on patient quality of life and healthcare expenditure.

This study will investigate the natural course of paclitaxel- and oxaliplatin induced peripheral neuropathy using novel diagnostic techniques. Multi-frequency vibrational technology has provided an objective method for the early detection of diabetic neuropathy. Our study will test the feasibility of this method within the field of clinical oncology and CIPN.

研究概览

研究类型

观察性的

注册 (实际的)

32

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Roskilde、丹麦、4000
        • Department of Clinical Oncology and Palliative Care

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

We will invite patients to participate in conjuction with their standard treatment. Patients have been diagnosed with ovarian cancer or colorectal cancer and have been scheduled to adjuvant treatment or metastatic treatment with one of the applicable drugs.

描述

Inclusion Criteria:

  • ≥ 18 years of age
  • A diagnosis of cancer.
  • Fulfil the criteria for starting chemotherapy.
  • Scheduled to undergo at least 4 courses of paclitaxel- or oxaliplatin-based chemotherapy.
  • No prior paclitaxel, oxaliplatin or other neurotoxic chemotherapy.

Exclusion Criteria:

  • Unable to complete PRO measures.
  • Previous neurotoxic chemotherapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Paclitaxel
Patients scheduled to receive paclitaxel as part of their standard treatment
We will observe the natural course of CIPN using multiple measurements
Oxaliplatin
Patients scheduled to receive oxaliplatin as part of their standard treatment
We will observe the natural course of CIPN using multiple measurements

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in VPT from baseline to 6 mo.
大体时间:through study completion, an average of 1 year and 6 months
For patients receiving paclitaxel: Difference in vibrograms from baseline compared to vibrograms after the end of the 6th course of chemotherapy or the last course of chemotherapy (if before course no. 6).
through study completion, an average of 1 year and 6 months
Difference in VPT from Baseline to 4 mo.
大体时间:through study completion, an average of 1 year and 6 months
For patients receiving oxaliplatin: Difference in vibrograms from baseline compared to vibrograms after the end of the 4th course of chemotherapy or the last course of chemotherapy (if before course no. 4).
through study completion, an average of 1 year and 6 months

次要结果测量

结果测量
措施说明
大体时间
Difference in PRO from baseline and during 1. course chemotherapy.
大体时间:up to 5 days
Difference in the NCCTG-CIPN Questionnaire from baseline compared to 4 days after initiation of chemotherapy course no. 1.
up to 5 days
Difference in VPT from baseline and during 1. course chemotherapy
大体时间:up to 5 days
Difference in the Vibrograms from baseline compared to 4 days after initiation of chemotherapy course no. 1.
up to 5 days
Difference in PRO from baseline to after chemotherapy course no. 3
大体时间:through study completion, an average of 1 year and 6 months
For patients receiving paclitaxel: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 3.
through study completion, an average of 1 year and 6 months
Difference in PRO from baseline to after chemotherapy course no. 2
大体时间:through study completion, an average of 1 year and 6 months
For patients receiving oxaliplatin: Difference in EORTC-QLQ-CIPN20 from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
through study completion, an average of 1 year and 6 months
Difference in VPT from baseline to af chemotherapy course no. 3
大体时间:through study completion, an average of 1 year and 6 months
For patients receiving paclitaxel: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 3.
through study completion, an average of 1 year and 6 months
Difference in VPT from baseline to af chemotherapy course no. 2
大体时间:through study completion, an average of 1 year and 6 months
For patients receiving oxaliplatin: Difference in the Vibrograms from baseline compared to after chemotherapy course no. 2. Some patients receiving oxaliplatin will have 6 courses of planned chemotherapy or planned metastatic treatment, in this case comparison will be made after chemotherapy course no. 3.
through study completion, an average of 1 year and 6 months
No. of discontinuations
大体时间:through study completion, an average of 1 year and 6 months
Number of patients not completing their planned courses of chemotherapy (reasons for discontinuation will be registered).
through study completion, an average of 1 year and 6 months
No. of dose reductions
大体时间:through study completion, an average of 1 year and 6 months
Number of patients that need reductions of chemotherapy dose (reasons will be registered)
through study completion, an average of 1 year and 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2019年11月20日

初级完成 (预期的)

2021年6月30日

研究完成 (预期的)

2021年9月30日

研究注册日期

首次提交

2019年11月7日

首先提交符合 QC 标准的

2019年11月14日

首次发布 (实际的)

2019年11月18日

研究记录更新

最后更新发布 (实际的)

2020年9月2日

上次提交的符合 QC 标准的更新

2020年9月1日

最后验证

2020年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅